Key result
Baroreflex activation therapy is reviewed as a potential treatment strategy aimed at reducing sympathetic function in patients with resistant hypertension or heart failure.
Why the study?
Many patients with hypertension fail to reach targets despite lifestyle and pharmacological therapy, and targeting sympathetic dysfunction with baroreflex activation therapy may benefit resistant hypertension and heart failure.
Does baroreflex activation therapy improve outcomes in patients with resistant hypertension or heart failure?
Does baroreflex activation therapy improve outcomes in patients with resistant hypertension or heart failure?
This review provides an overview of baroreflex activation therapy as a potential treatment strategy for patients with resistant hypertension or heart failure.
Baroreflex activation therapy merits evaluation in resistant hypertension and heart failure; leaves open its clinical role pending randomized outcome trials.
Hypertension and heart failure are important contributors to global morbidity and mortality. Despite therapeutic lifestyle and pharmacological measures, a significant proportion of people with hypertension do not reach treatment targets. Patients with resistant or poorly controlled hypertension are at significantly increased risk of cardiovascular events, including heart failure. Since dysfunction of the sympathetic nervous system appears to play a key role in the development and progression of both hypertension and heart failure, these patients may benefit from treatment modalities aimed at reducing sympathetic function. The purpose of this paper is to provide an overview of baroreflex activation therapy as a potential treatment strategy in patients with resistant hypertension or heart failure.
No takes yet. Share an insight, caveat, or question.
Kristensen et al. (2020) conducted a review in Resistant hypertension and heart failure. Baroreflex activation therapy was evaluated. Baroreflex activation therapy is reviewed as a potential treatment strategy aimed at reducing sympathetic function in patients with resistant hypertension or heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: